Insulin and Blood Sugar in Pregnancy: What Every Pregnant Patient Needs to Know

How Pregnancy Alters Insulin Sensitivity and Glucose Regulation

Insulin sensitivity drops progressively across all three trimesters, driven by placental hormones. The placenta secretes human placental lactogen, progesterone, cortisol, and tumor necrosis factor-alpha, all of which antagonize insulin signaling at the receptor and post-receptor levels. By 26 weeks, insulin-stimulated glucose disposal may fall by 40 to 60% compared with the non-pregnant state, according to data published in Diabetes Care [1].

In women without underlying metabolic disease, pancreatic beta-cell mass expands by roughly 1.4-fold to compensate. When that compensatory response fails, gestational diabetes develops. The American Diabetes Association's 2024 Standards of Care define GDM as "diabetes diagnosed in the second or third trimester of pregnancy that was not clearly overt diabetes prior to gestation" [2].

Fasting glucose also behaves differently during pregnancy. Even in normoglycemic women, fasting plasma glucose falls about 10 to 15 mg/dL below non-pregnant norms because the fetus continuously draws glucose across the placenta. This physiologic fall matters clinically: fasting values that look normal on standard reference ranges may actually represent impaired regulation in a pregnant patient.

The practical consequence is that glucose monitoring schedules used outside of pregnancy, such as checking only a fasting value once a day, are insufficient. Both fasting and one- to two-hour postprandial checks are needed to capture the full glycemic picture [2].

Diagnosing Gestational Diabetes: Thresholds and Screening Protocols

ACOG recommends universal GDM screening between 24 and 28 weeks using either a one-step or two-step approach. The two-step method remains the standard in the United States [3].

Step one: a non-fasting 50-gram oral glucose challenge test. A one-hour plasma glucose value of 130 to 140 mg/dL (the cut-off varies by institution) is considered screen-positive. Step two: a fasting 100-gram, three-hour OGTT. GDM is diagnosed when two or more values meet or exceed Carpenter-Coustan thresholds: fasting >95 mg/dL, one-hour >180 mg/dL, two-hour >155 mg/dL, three-hour >140 mg/dL [3].

Women with risk factors such as pre-pregnancy BMI >30 kg/m², prior GDM, first-degree relative with type 2 diabetes, or polycystic ovary syndrome should be screened at the first prenatal visit for overt pre-existing diabetes using fasting plasma glucose or HbA1c [2]. An HbA1c of 6.5% or higher at the first prenatal visit signals pre-existing diabetes, not GDM.

The HAPO study (N=23,316) established the continuous relationship between maternal glucose and adverse perinatal outcomes, demonstrating that even glucose levels below traditional diagnostic thresholds were associated with increased rates of birth weight above the 90th percentile, primary cesarean delivery, and neonatal hypoglycemia [4]. That evidence base drove the one-step 75-gram OGTT criteria championed by the International Association of Diabetes and Pregnancy Study Groups (IADPSG).

Blood Glucose Targets During Pregnancy

The targets below come directly from the ADA's 2024 Standards of Care for Diabetes in Pregnancy [2]:

• Fasting: <95 mg/dL
• One-hour postprandial: <140 mg/dL
• Two-hour postprandial: <120 mg/dL

HbA1c is a less reliable pregnancy monitor because red blood cell turnover accelerates during pregnancy, reducing mean erythrocyte lifespan and falsely lowering HbA1c readings. Despite this limitation, the ADA recommends an HbA1c target of 6 to 7% for most pregnant patients with pre-existing diabetes, with individualization toward 6 to 6.5% if that level is achievable without significant hypoglycemia [2].

Continuous glucose monitoring changes the conversation. The CONCEPTT trial (N=325) randomized pregnant women with type 1 diabetes to CGM versus standard monitoring and found that CGM use reduced the rate of large-for-gestational-age infants by 21% (relative risk 0.79 to 95% CI 0.64, 0.99) and shortened NICU admissions by approximately one day [5]. CGM time-in-range of 63 to 140 mg/dL for at least 70% of readings is now cited as a complementary target alongside the point-based thresholds above [2].

Insulin Therapy for Gestational and Pre-Existing Diabetes in Pregnancy

Medical nutrition therapy and moderate physical activity are first-line for GDM. About 70 to 85% of GDM cases can be managed with diet alone. When glucose targets are not met within one to two weeks of lifestyle modification, pharmacologic therapy begins.

Why insulin is preferred over oral agents. Metformin crosses the placenta freely, and long-term offspring data beyond five years of age remain limited. Glyburide crosses the placenta at measurable concentrations and carries a higher risk of neonatal hypoglycemia. A 2015 Cochrane review found metformin was not inferior to insulin for primary GDM outcomes but acknowledged that the fetal exposure question was unresolved [6]. ACOG accepts metformin and glyburide as alternatives when insulin is declined or inaccessible, but insulin remains the agent with the longest safety record in pregnancy [3].

Insulin formulations and safety data. NPH and regular human insulin carry formal FDA approval in pregnancy. The rapid-acting analogs insulin aspart (NovoLog) and insulin lispro (Humalog) do not carry an explicit FDA label for pregnancy but have substantial observational and trial data demonstrating fetal safety [7]. A 2018 randomized trial (DALI, N=270) found insulin aspart produced equivalent glycemic control with lower hypoglycemia rates than regular insulin in pregnant women with type 1 diabetes [7]. Insulin glargine and insulin detemir are used off-label; detemir has a large randomized trial (N=310, the Mathiesen trial) showing non-inferiority to NPH with fewer nocturnal hypoglycemic episodes [8].

Dose escalation across trimesters. In the first trimester, insulin requirements often fall transiently as nausea limits carbohydrate intake. By the second trimester, total daily dose (TDD) begins to climb. By 36 to 38 weeks, TDD in type 1 diabetes commonly reaches 1.0, 1.5 units per kilogram per day, roughly double the pre-pregnancy requirement [2]. After delivery, insulin resistance resolves abruptly: doses must drop within 24 to 48 hours to prevent postpartum hypoglycemia.

A basal-bolus regimen using a long-acting insulin once daily (detemir or glargine) plus a rapid-acting analog with each meal mirrors physiologic insulin secretion most closely and allows precise dose adjustment at each meal without adjusting the whole regimen. Insulin pumps (continuous subcutaneous insulin infusion) combined with CGM, so-called "closed-loop" systems, have shown promise in small trials in pregnant women with type 1 diabetes but are not yet standard of care in this population [9].

Practical titration guide for GDM requiring insulin. The HealthRX medical team uses the following decision framework for initial insulin prescribing in GDM patients whose diet has failed after two weeks:

1. If fasting glucose alone exceeds 95 mg/dL: start bedtime NPH at 0.1, 0.2 units/kg of current body weight.
2. If one- or two-hour postprandial values exceed targets at a single meal: add a rapid-acting analog at that meal only, starting at 1, 2 units and titrating by 1, 2 units every 3 days.
3. If multiple meals exceed targets: convert to full basal-bolus.
4. Reassess TDD every 1 to 2 weeks using the prior week's glucose log; increase by 10 to 20% if more than two readings per day exceed targets.

This stepwise approach avoids over-insulinization in early GDM while giving precise control when needed.

Maternal and Fetal Risks of Poorly Controlled Blood Sugar

Elevated maternal glucose is the primary driver of fetal hyperinsulinemia. The fetal pancreas responds to glucose crossing the placenta by secreting excess insulin, which acts as a fetal growth factor. The result is macrosomia (birth weight above 4 to 000 g), which increases the risk of shoulder dystocia, brachial plexus injury, and emergency cesarean delivery.

The HAPO study (N=23,316) demonstrated a linear association: for every 1 standard-deviation increase in fasting glucose above the study mean, the odds of a large-for-gestational-age infant rose 38% [4]. Beyond fetal size, poorly controlled glucose increases rates of preeclampsia by approximately 3-fold and of neonatal hypoglycemia (plasma glucose <40 mg/dL) by 2-fold compared with well-controlled GDM [2].

For women with pre-existing type 1 or type 2 diabetes, the additional risk of congenital malformations is concentrated in the first eight weeks, when organogenesis occurs. An HbA1c above 10% in the periconception period raises the relative risk of major cardiac or neural tube defects by 3, 5-fold [10]. Achieving HbA1c below 6.5% before conception, while avoiding hypoglycemia, is the single most effective intervention for reducing congenital anomalies.

Insulin and Blood Sugar in Older Adults

Aging reduces beta-cell reserve and increases hepatic insulin resistance, making hyperglycemia more common and more difficult to treat. Older adults face additional complexity: hypoglycemia recognition is blunted because adrenergic symptoms (tremor, palpitations) may be absent or masked by beta-blocker therapy. The ADA recommends less stringent HbA1c targets, 7.5 to 8.0% for older adults with multiple comorbidities or limited life expectancy, to reduce the burden of hypoglycemia [2].

In older adults who are pregnant (defined by ACOG as advanced maternal age, 35 years or older), both risks converge. GDM incidence is substantially higher in this group, approximately 14 to 15% versus 5 to 7% in women under 30, and insulin dose requirements may differ from younger cohorts due to baseline insulin resistance [3]. Careful fasting glucose monitoring and conservative initial insulin doses (starting at 0.1 units/kg rather than 0.2 units/kg) reduce hypoglycemia risk in this subgroup.

Insulin and Blood Sugar in Children

Type 1 diabetes accounts for 85 to 90% of childhood-onset diabetes in the United States, and all children with type 1 diabetes require insulin. The ADA's 2024 pediatric standards recommend HbA1c below 7.0% for most children and adolescents, with less stringent targets (7.5%) considered when hypoglycemia risk is high or self-management resources are limited [2].

Pregnancy in adolescents with pre-existing type 1 diabetes represents one of the most complex situations in obstetric endocrinology. Insulin requirements in adolescent pregnancy can be unpredictable because puberty-related growth hormone secretion adds another layer of insulin resistance on top of the placental hormones described earlier. Adolescent patients should be transitioned to a basal-bolus regimen with CGM before conception if possible, and HbA1c below 6.5% should be the pre-conception target [2].

Insulin Dosing in Renal Disease

Chronic kidney disease (CKD) alters insulin pharmacokinetics in two opposing ways. First, the kidney normally degrades approximately 25 to 40% of secreted insulin; as glomerular filtration rate falls below 30 mL/min/1.73m², this clearance decreases, so exogenous insulin accumulates and hypoglycemia risk rises. Second, uremia impairs hepatic gluconeogenesis and increases peripheral insulin resistance. The net effect is unpredictable and requires more frequent monitoring.

In pregnant women with diabetic nephropathy (CKD stage 3 or higher), insulin requirements may fall dramatically in the third trimester despite rising placental insulin resistance. The ACOG Practice Bulletin on pregestational diabetes recommends fasting and postprandial monitoring at least six times per day in women with nephropathy, and dose reductions of 20 to 30% should be anticipated as eGFR falls below 30 mL/min [3]. All oral hypoglycemics except some formulations of metformin are contraindicated at eGFR <30; insulin remains the only safe choice [2].

Insulin and Blood Sugar in Heart Failure

Hyperglycemia and heart failure share bidirectional pathophysiology. Elevated glucose causes endothelial dysfunction, myocardial steatosis, and oxidative stress; simultaneously, heart failure drives neurohormonal activation (sympathetic and renin-angiotensin-aldosterone) that increases hepatic glucose production and worsens insulin resistance. In the UKPDS follow-up (17 years, N=3,277), each 1% rise in HbA1c was associated with an 8% increase in heart failure risk [11].

For pregnant women who enter pregnancy with pre-existing cardiomyopathy or peripartum cardiomyopathy developing during gestation, glucose management must balance tight control against hypoglycemia. Hypoglycemia triggers catecholamine surges that increase heart rate, reduce diastolic filling time, and can precipitate arrhythmia in a compromised myocardium. An HbA1c target of 7 to 7.5% rather than 6 to 6.5% may be appropriate in this subgroup, in direct consultation with cardiology [2].

SGLT-2 inhibitors, which reduce heart failure hospitalization by 25% in the DAPA-HF trial (N=4,744) [12], are contraindicated in pregnancy. GLP-1 receptor agonists such as semaglutide and liraglutide are also contraindicated. Insulin remains the cornerstone of therapy, and doses should be titrated conservatively given the blunted hypoglycemia response that often accompanies advanced heart failure.

Postpartum Glucose Management and Long-Term Risk

After delivery, the placenta is removed and insulin resistance falls within 24 to 48 hours. Women on insulin for GDM can typically discontinue it immediately postpartum. Women with pre-existing diabetes should reduce TDD by 30 to 50% on the day of delivery and re-titrate over the following week based on capillary glucose readings.

The ADA and ACOG both recommend a 75-gram two-hour OGTT at 4 to 12 weeks postpartum for all women with GDM [2, 3]. This test should use non-pregnancy diagnostic criteria (diabetes: fasting >126 mg/dL or 2-hour >200 mg/dL). If normal, annual fasting glucose or HbA1c screening should continue indefinitely, because the 10-year cumulative incidence of type 2 diabetes in women with prior GDM reaches 50% in some cohorts [13].

Breastfeeding reduces postpartum glucose levels and may reduce GDM recurrence risk in a subsequent pregnancy. A 2010 prospective study (N=704) found that longer lactation duration was associated with lower 2-hour post-load glucose at two years postpartum [14]. Metformin, which is excreted in breast milk at low concentrations, is considered compatible with breastfeeding by most lactation authorities; insulin does not transfer to breast milk in biologically significant amounts.